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Background & aims: The requirement of leucine and essential amino acids (EAA) to stimulate muscle
protein synthesis increases with age. To target muscle anabolism it is suggested that higher postprandial
blood levels of leucine and EAA are needed in older people. The aim was to evaluate the impact of oral
nutritional supplements with distinct protein source and energy density, resembling mixed meals, on
serum amino acid proﬁles and on gastrointestinal behaviour.
Methods: Four iso-nitrogenous protein (21 g) supplements were studied containing leucine-enriched
whey protein with 150/320 kcal (W150/W320) or casein protein with 150/320 kcal (C150/C320); all
products contained carbohydrates (10 or 32 g) and fat (3 or 12 g). Postprandial serum AA proﬁles were
evaluated in twelve healthy, older subjects who participated in a randomized, controlled, single blind,
cross-over study. Gastrointestinal behaviour was studied in vitro by looking at gastric coagulation and
cumulative intestinal protein digestion over time.
Results: The peak serum leucine concentration was twofold higher for W150 vs. C150 (521 ± 15 vs.
260 ± 15 mmol/L, p < 0.001), higher for W320 vs. C320 (406 ± 15 vs. 228 ± 15 mmol/L, p < 0.001), and
higher for low-caloric vs. high-caloric products (p < 0.001 for pooled analyses; p < 0.001 for interaction
protein source*caloric density). Similar effects were observed for the peak concentrations of EAA and
total AA (TAA). In vitro gastric coagulation was observed only for the casein protein supplements. In-
testinal digestion for 90 min resulted in higher levels of free TAA, EAA, and leucine for W150 vs. C150, for
W150 vs. W320, and for C150 vs. C320 (p < 0.0125).
Conclusions: A low caloric leucine-enriched whey protein nutritional supplement provides a higher rise
in serum levels of TAA, EAA and leucine compared to casein protein or high caloric products in healthy,
elderly subjects. These differences appear to be mediated in part by the gastrointestinal behaviour of
these products.
Clinical trial registration: ClinicalTrials.gov: NCT02013466.
© 2015 Nutricia Research. Published by Elsevier Ltd and European Society for Clinical Nutrition and
Metabolism. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).resented at ESPEN 2010, Nice
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c-nd/4.0/).1. Introduction
Aging often coincides with loss of muscle mass, strength and
function, known as sarcopenia [1]. Sarcopenia, a geriatric syndrome
closely linked to physical frailty, has a substantial impact on the
quality of life of the individual and increases the risk of disability
and hospitalization [1]. Sarcopenia has been linked to a decreasedlinical Nutrition and Metabolism. This is an open access article under the CC BY-NC-
Table 1
Composition of the study products.
Nutrients W150 C150 W320 C320
Energy (kcal) 150 150 320 320
Protein (En%) 56 56 26 26
Carbohydrates (En%) 26 26 40 40
Fat (En%) 18 18 34 34
Total protein (g) 21 21 21 21
Whey protein (g) 20 e 20 e
Casein protein (g) e 21 e 21
Free BCAA (g) 1 0 1 0
Total leucine (g)a 3 2 3 2
Total EAA (g)a 10 9 10 9
Carbohydrates (g) 11b 10 33b 32
Fat (g) 3 3 12 12
BCAA, branched chain amino acids; EAA, essential amino acids.
a Provided by protein and free BCAA.
b Includes citric acid to obtain an acidic product.
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acids (EAA) [2e5].
Muscle protein synthesis has been shown to respond to extra-
cellular EAA concentration [6], subsequent transport, and intra-
cellular amino acid rate of deposition in muscle [7,8]. A high
amount of EAA and leucine in one single bolus has also been shown
to enable stimulation of muscle protein synthesis in older adults
[9e12]. Accordingly, higher postprandial blood levels of EAA and
leucine correlate to a higher muscle protein synthesis rate [13,14].
This suggests that the postprandial proﬁle by which amino acids
and especially EAA and leucine appear in blood and become
available for muscle, is relevant for subsequent stimulation of
muscle protein synthesis. This appears to be even more important
with advancing age, conditions of inﬂammation and insulin resis-
tance. The threshold needed to trigger intracellular translation
initiation pathways to activate protein synthesis is likely higher
under these conditions [15].
The quantity and source of dietary proteins have been shown
to impact postprandial blood levels of EAA and leucine [16]. As a
result, the concept of “fast/slow” protein was implemented to
indicate the postprandial proﬁle of amino acids appearing in the
systemic circulation [17,18]. As an example, the dairy proteins
whey and casein contain a similar amount of EAA, but blood EAA
levels increased faster and to a higher level after the intake of
whey protein [14,19]. Therefore, whey is considered a “fast”
protein, while casein is a “slow” protein. A difference in gastric
emptying and digestion and absorption kinetics between casein
and whey [14,20,21] are suggested as an underlying factor.
Distinct factors have been shown to modulate gastric emptying
and the gastrointestinal digestion of nutritional compositions.
Gastric coagulation of casein with formation of solid particles
[17], is an example of a physiological phenomenon that is known
to delay gastric emptying of casein [21,22]. Another example is
the difference in sequential release of casein and whey-derived
peptides in the jejunum [23], that is indicative of distinct hy-
drolysis kinetics of casein and whey. Moreover, it is known that
the higher the caloric density of nutrition the more it delays
gastric emptying [24,25]. Supplementing sucrose to a casein or
milk protein indeed delayed protein digestion and absorption
kinetics [26] and increased the oro-ileal transit time [27]. How-
ever, the relevance of gastric coagulation and of intestinal
digestion rate for postprandial amino acid proﬁles and systemic
amino acid bioavailability of casein and whey protein-containing
supplements, i.e. resembling mixed meals of different caloric
densities, is less well known.
Our primary study aim was to evaluate postprandial blood
amino acids proﬁles in healthy older people after the intake of a
leucine-enriched whey protein nutritional supplement compared
to an iso-caloric and iso-nitrogenous control product containing
casein protein. While distinct effects of intact whey and casein
protein on blood amino acid proﬁles in older people have been
reported, the use of carbohydrates and fat besides protein is less
well known. This is relevant as it represents conventional products
or a ‘mixedmeal’. Secondly, we aimed to study the impact of caloric
density of the whey and casein products on postprandial amino
acid proﬁles and systemic amino acid bioavailability, which was not
studied like this before. Third, we aimed to understand the rele-
vance of distinct gastrointestinal behaviour of the nutritional sup-
plements for postprandial amino acid proﬁles. While in vivo
digestion studies with jejunal sampling and/or intrinsically labelled
proteins are preferred, these measures are also invasive and require
that nutritionally supplements are produced with intrinsically
labelled proteins. Therefore, we applied in vitromodels to compare
the coagulation behaviour and protein digestion rate (initial and
overall cumulative digestion over time) of the nutritionalsupplements, under conditions closest to those found in a healthy,
elderly population.
2. Materials and methods
2.1. Subjects in clinical study
Fifteen healthy adults that were 65 years or older were screened.
A total of 12 subjects (5 male) were enrolled in the study. Subjects
who signed the informed consent had a Body Mass Index (BMI)
between 21 and 30 kg/m2, and were willing and able to comply
with the protocol. The protocol included adhering to a fasting state
from 22:00 h the day prior to the study visits, refraining from
alcohol consumption (24 h) and intense physical activities (24 h)
before the study visits and not changing dietary habits for the
duration of the study. Subjects with a (history of) gastrointestinal
disease, or those that had been diagnosed with, or were suspected
of having, diabetes mellitus (fasting glucose  7.0 mmol/L) were
excluded from participation. Other exclusion criteria were: infec-
tion or fever in the past 7 days, medication use (antibiotics within 3
weeks of study entry, current use of corticosteroids or hormones,
and the use of antacids or any medication inﬂuencing gastric acid
production), known allergy to milk or milk products, lactose
intolerance and known galactosaemia. Moreover, subjects were
excluded when they currently participated in a weight loss or
muscle strengthening program or used nutritional supplements
that contained proteins or amino acids within one week of study
entry, as well as those who had smoked for the past 3 months or
abused alcohol or drugs. The Modiﬁed Baecke Questionnaire for
Older People [28] was completed to measure the normal physical
activity level. Body weight and height were measured.
Supplementary Fig. 1 shows the Consort ﬂow diagram.
All subjects were informed of the study procedures and possible
risks before signing informed consent. The subject enrolment and
study conduction was done by Ampha B.V. (clinical research unit,
Nijmegen, the Netherlands) according to ICH-GCP principles, and in
complied with the principles of the ‘Declaration of Helsinki’ (59th
WMA General Assembly, Seoul, October 2008) and the local laws
and regulations. The Independent Review Board Nijmegen (IRBN),
the Netherlands, approved the study. This trial is registered at the
ClinicalTrials.gov Trial Register under number NCT02013466.
2.2. Study products
Four study products, differing in protein source and caloric
density (Table 1), were tested in vivo and in vitro. Two products
composed a leucine-enriched whey protein nutritional supplement
Fig. 1. Semi-dynamic model of the gastrointestinal tract. The model consisted of a)
Computer controlled parallel bioreactor system, and b) Single bioreactor with over-
head agitation. c) Time schedule.
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with 150 kcal (W150) or 320 kcal (W320), respectively. The other
products contained an iso-nitrogenous amount of casein (21 g
casein protein (from calcium caseinate)) with 150 kcal (C150) or
320 kcal (C320), respectively. Additional calories were added as fat
and carbohydrates, similar to conventional medical nutrition sup-
plements. The osmolality of the 320 kcal products was higher
(239e248 mOsm/kg) compared with the 150 kcal products
(131e139 mOsm/kg). The pH of the whey products was acidic (4.0),
while pH was neutral for the casein products (6.6). Subjects
consumed the complete products within 5 min. Site staff, not
involved in the study, mixed the study products (as powders) with
water to a volume of 300 ml before consumption.
2.3. Clinical study design (in vivo study)
This clinical study was a randomised, controlled, single-blinded,
cross-over, single centre study. Subjects eligible for participation
were randomly allocated, by using three 4  4 Latin squares, to
obtain a unique order of the study products. Study products were
packaged indistinguishably and coded. Aside from a noticeable
difference in weight between the low and high-caloric sachets,
study staff was blinded to the origin of the study products until
completion all data were included in the study database.
Subjects visited the research location in a fasting state on four
separate mornings. A ﬂexible 18-22 gauge catheter was placed into
a forearm vein for blood sampling. Fasting blood samples were
collected at baseline for serum C-reactive protein (CRP), albumin,
glucose, insulin, and amino acid concentrations (t ¼ 15 min), and
a second basal sample for amino acid, glucose and insulin con-
centrations was taken just before product intake. After consump-
tion of the study product (t0), repeated blood samples were drawn
over the next 4 h, at 15, 30, 45, 60, 75, 90,105,120,150,180, 210, and
240 min for analyses of amino acids, glucose and insulin concen-
trations. Before product consumption and at 240 min after product
intake, blood pressure and heart rate were measured, and a toler-
ance questionnaire was completed to measure the intensity of
gastrointestinal symptoms (heartburn, belching, nausea, vomiting,
abdominal distension, ﬂatulence, diarrhoea, and constipation),
light-headedness, headache, thirst and dry mouth.
Visits were planned with intervals of 7e10 days between the
visits. A follow-up phone call was scheduled approximately one
week after the last study visit to identify adverse events and eval-
uate the tolerance of the intervention. Throughout the study, the
use of relevant concomitant medication and nutritional supple-
ment intake was recorded. Supplementary Fig. 2 illustrated the
clinical study design.
Stopping guidelines with premature discontinuation of partici-
pation in the study included cases when further participation was
considered a health risk for a subject (at supervising clinicians
discretion), and cases inwhich a subject had decided to resign from
further participation in the study.
2.4. In vitro digestion modelling (in vitro study)
A semi-dynamic two-step gastrointestinal model was used, as
illustrated in Fig. 1. The model has continuous pH control, digestive
juice addition and separate pre-deﬁned gastric and intestinal steps.
The model consists of eight parallel bioreactors that are computer
controlled. Each is equipped with a pH electrode and four dosing-
lines with separate substrate pumps (Dasgip AG, Jülich, Germany)
(Fig. 1a and b). Gastrointestinal conditions were simulated by pH
and substrate pump control at 37 C as described previously [22].
The ﬂow, volumes and compositions of secretions were based on
what is used in a dynamic model of the gastro-intestinal tract[29,30], as described earlier in detail [22]. For the current study, the
approachwas adapted: a) using reactors with a larger volume (to ﬁt
300 ml), therefore no scaling was necessary, b) adding a small in-
testinal phase, c) adapting gastric secretion to elderly conditions by
lowering pepsin and lipase concentration based on the decreased
peak pepsin output observed in elderly, i.e. 52%, as compared to
healthy young adults [31], and d) using overhead agitation at
90 rpmwith three perpendicularly placed 45 two-blade impellers,
instead of magnetic stirring, for adequate mixing of the study
product and digestive juices with lower shear. The four different
substrates were a) 1 M HCl and b) 1 M NaHCO3 and 3 M NaOH to
adjust the pH, and c) artiﬁcial gastric juice and d) pancreatin/bile
mixture containing 2% w/v porcine bile extract (Sigma B8631),
1.75% w/v pancreatin (Pancrex V, Pﬁzer) supernatant, 0.25% w/v
NaCl, 0.03% KCl, and 0.015% w/v CaCl2$H2O. Artiﬁcial saliva was
added manually.
Experiments were done in triplicate (n ¼ 3) with the investi-
gator blinded for the composition of the nutritional supplements.
Gastric digestion was simulated for 90 min. During this period the
pH was lowered according to a predeﬁned curve that is based on
the acid secretion capacity of older people and the pH of the sup-
plements [32]. The pHwas lowered from 4.0 to 2.2 within 90min in
whey compositions and from 6.6 to 3.0 in casein supplements
within 90 min. In one set of the experiments, the simulation was
discontinued and the gastric contents were analysed for solid
particles, i.e. coagulate fractions. In another set of experiments, the
ﬁrst 90-min phase of gastric digestion was followed by a 90-min
simulation phase of small intestinal digestion, allowing the sys-
tem ten minutes between the 2 phases to bring the pH to the set
start pH (6.5) of the intestinal phase. The set intestinal pH curve
was the same for all supplements, i.e. an increase to pH 7.2 in
90 min. At the start of the experiment, 50 ml of saliva was added
manually (Fig. 1c). The ﬂow rate for gastric juice was 0.5 ml/min. In
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added as a shot to simulate the gastric juice already present in the
stomach. The secretion of the pancreatin/bile mixture was at a rate
of 1.0 ml/min. At the start of the intestinal phase, 1 ml of trypsin
solution (0.2% w/v (sigma T9201)) was added manually to simulate
the action of enterokinase on trypsinogen from the pancreatin. In
the ﬁrst 5min, 50ml of pancreatin/bile mixturewas added as a shot
to simulate the intestinal contents at the time of ingestion.
2.5. Sample processing, analyses, and calculations
2.5.1. Blood samples (in vivo)
Blood was sampled in serum tubes. Serum was obtained by
centrifuging whole blood at room temperature for 15min at 1000 g.
All serum samples were stored at 80 C until further analyses.
2.5.2. Coagulate fractions (in vitro)
After 90 min of simulated gastric digestion, the content of the
reactors was poured over three analytical sieves. The mesh widths
of the sequential sieves was 2 mm, 1 mm, and 0.25 mm (Retsch,
VWR, Amsterdam, Netherlands) in order to separate insoluble
particles by particle diameter (D) in three fractions: larger than
2 mm (D>2), between 1 and 2 mm (D<1e2>), between 0.25 and
1 mm (D<0.25e1>). The dry matter content of each fraction was
determined as described previously [20].
2.5.3. Protein digestion rate (in vitro)
Sampling over time in the intestinal phase enables us to gain
insights into the initial digestion rate (ﬁrst one-two samples (t10
and t20), early intestinal phase) and the overall digestion rate (later
samples, representing cumulative digestion over a maximum 90-
min intestinal period). Measurement of the accumulation of pro-
tein digestion products was done with two distinct, complemen-
tary methods. The analysis was focused on the end products of
pancreatic enzymes. It has been found in vivo that the absorbable
fraction of protein digestion products consists of free amino acids
and peptides built of two to six amino acids, in a ratio of 25:75mol%
of free and peptide-bound amino acids respectively [33]. Therefore,
1kD was chosen as the upper limit as done by others [34], and
peptides smaller than 1kD and free amino acids were quantiﬁed.
2.5.4. Peptide analysis (from in vitro study)
Peptides were quantiﬁed using size exclusion chromatography
(SEC). The HPLC system (Shimadzu) was equipped with a Superdex
Peptide 10/300 column (GE Healthcare 17-5176-01). Detection of
peptide bonds in the eluent (25%wt acetonitrile, 0.16%wt triﬂuor-
acetic acid) was by done by UV absorption, l ¼ 200 nm. The rela-
tionship between elution time and molecular weight was
calibrated using ten distinct small proteins and peptides ranging
from 12kD to 188D, of which ﬁve were smaller than 1 kD. The
correlation coefﬁcient of linear ﬁt between elution time and mo-
lecular weight was 0.980 between 9.2 and 19.2 min. The AUC was
calculated from 15.3 min (1kD) to 23 min to exclude contribution of
free aromatic amino acids that absorb at this wavelength.
2.5.5. Analysis of free amino acids (from in vivo and in vitro studies)
Proteins and large peptides were precipitated with perchloric
acid. After ﬁltration, the amount of the free amino acids in the
supernatant is determined by UFLC using a pre-column derivati-
zation with o-phtaldialdehyde and ﬂuorimetry as detection [35].
2.5.6. Analysis of other blood parameters (from in vivo study)
Glucose and albumin concentrations were measured using
colorimetry. Turbidimetry was used for analysis of CRP. Insulin
concentrations were measured by immunoluminometric assay.2.5.7. Calculations and primary/secondary outcome parameters
(in vivo)
For serum free leucine, EAA (sum of histidine, isoleucine,
leucine, lysine, methionine, phenylalanine, threonine, tryptophan,
and valine), and the sum of all amino acids (TAA: alanine, arginine,
asparagine, aspartic acid, citrulline, cysteine, glutamic acid, gluta-
mine, glycine, serine, taurine, histidine, isoleucine, leucine, lysine,
methionine, phenylalanine, threonine, tryptophan, and valine;
tyrosine was excluded because of technical problems in the anal-
ysis) the following parameters were calculated: the maximum (or
peak) concentration, the maximum increment from baseline
(delta), the iAUC (from baseline, during 4 h after product intake)
and the time to reach half the serum leucine iAUC (t1/2). For serum
glucose and insulin, the maximum (or peak) and iAUC values were
calculated.
The primary outcome parameter of the clinical study was the
maximum leucine level; secondary parameters were maximum
levels of EAA, TAA, glucose and insulin, the iAUC of leucine, glucose
and insulin, and t1/2 of leucine. As a deviation to the protocol but
before data analyses, iAUC and t1/2 of EAA and TAA were added as
secondary parameters.2.6. Statistical analysis
Power analysis for the in vivo study was based on an estimated
100 mmol/L difference in peak leucine level between W150 and
C150 with a standard deviation of difference of 60 mmol/L for
whey and 54 mmol/L for casein as estimated from Dangin et al.
[19], an a of 0.05, a power of 80% and dropout rate of 33%. All
in vivo serum variables (amino acids, glucose and insulin con-
centrations) were analysed using a mixed model with a random
effect for subjects, a ﬁxed effect for the factors protein (2 levels:
whey, casein) and caloric density (2 levels: low, high), and a ﬁxed
interaction of protein*caloric density. Statistical signiﬁcance of
these pooled analyses was deﬁned as a two-tailed p < 0.05. In
separate mixed model analyses, the difference between W150 and
C150, between W150 and W320, between C150 and C320 and
between W320 and C320 were analysed. Statistical signiﬁcance
was deﬁned as a two-tailed p < 0.0125 in order to correct for
multiple comparisons. Baseline value (for leucine, EAA, AA, insulin,
or glucose), serum albumin, and serum CRP were included as
covariates in the respective mixed model. The concentration at t0
was used for baseline value when concentrations at t-15 and t0
were statistically signiﬁcantly different using mixed model anal-
ysis. In case of no statistical difference, the mean concentration of
the 2 time points at baseline was taken. For peak leucine, addi-
tional analyses were performed using age, physical activity level,
sex or BMI (categories 25 and >25 kg/m2) as additional cova-
riates in the mixed model. SAS 9.1.3 (SAS Institute; PROC MIXED
procedure) software was used. In vivo data are presented as esti-
mated marginal mean (EMM) with SE, as derived from the mixed
model, unless otherwise stated.
In vitro gastric coagulation data were analysed with Student's t-
test, 2-tailed, equal variances assumed, and differences were
considered signiﬁcant when p < 0.05. In vitro protein digestion
kinetics data was analysed using ANOVA univariate analysis with
LSD post hoc test. One on the triplicate measures for W150 was
excluded from the dataset because of technical malfunction of the
bioreactor. Because there were no more supplements available for
the study, the statistical interaction model was used to determine
estimated means. Differences were considered signiﬁcant when
p < 0.0125, in order to correct for multiple comparisons. Statistics
were performed using SPSS 15.0 for Windows. Data are shown as
raw mean with SEM, unless stated otherwise.
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3.1. Subjects
The ﬁrst subject was included in the study on October 27, 2008.
The last subject completed the study on February 19, 2009. Ten out
of 12 subjects completed all visits. Two subjects terminated the
study early, but had at least 1 study visit completed. None of the
randomized subjects violated the eligibility criteria during the
study or had other protocol violations. Therefore, all subjects were
included in the population analysis, and descriptive and statistical
analyses were performed on the 12 subjects (Supplementary Fig. 1).
Subjects' characteristics are listed in Table 2. No related serious
adverse events were observed during the study. A few mild to
moderate adverse events were reported with no clinically relevant
difference in occurrence between the products. There were no
clinically relevant differences in incidence of GI symptoms between
treatments.3.2. Serum concentrations of amino acids, glucose, and insulin
Proﬁles for serum leucine, EAA, and TAA are illustrated in Fig. 2,
and for serum glucose and insulin in Fig. 3. Values and statistical
comparison between groups at baseline, peak, delta, iAUC and t1/2
for serum leucine, EAA, and TAA are listed in Table 3. Baseline
values for serum amino acids, glucose and insulin were well
balanced between the study visits.
Pooled analysis of the low-caloric vs. the high-caloric products
(W150 and C150 vs. W320 and C320) showed a signiﬁcantly higher
peak and iAUC of serum leucine, EAA, and TAA for the low-caloric vs
the high-caloric products (p < 0.001). The caloric density effect was
stronger for the leucine-enriched whey protein supplements
(W150 vs. W320) than for the casein protein supplements (C150 vs.
C320) on peak levels of serum leucine (effect size (EMM ± SE) of
114 ± 14.3 mmol/L (p < 0.001) vs 32 ± 14.8 mmol/L (p ¼ 0.042)),
serum EAA (effect size of 395 ± 49.2 mmol/L (p < 0.001) vs
120 ± 49.6 mmol/L (p ¼ 0.023), and serum TAA (effect size of
546 ± 79.0 mmol/L (p < 0.001) vs 247 ± 76.3 mmol/L (p ¼ 0.003)).
This is also reﬂected by the signiﬁcant interaction effect between
protein source and caloric density (p < 0.001 for peak levels of
leucine and EAA, p¼ 0.015 for TAA). Including age, physical activity
level, gender or BMI in the mixed model for peak leucine did not
change the signiﬁcance of the effect.
Peak serum glucose concentration was 5.54 ± 0.18 and
6.05 ± 0.19 mmol/L after intake of W150 and C150, respectivelyTable 2
Subject characteristics.












BMI (kg/m2) 26.0 ± 2.6
Serum albumin
(g/L)
41.2 ± 1.89 39.8 ± 1.32 40.3 ± 2.23 40.9 ± 1.87
Serum CRP
(mg/L)




All data are means ± SD, except for sex; n ¼ 12 (ITT).
a Total score, derived from the Modiﬁed Baecke Questionnaire for Older People
[28].(p¼ 0.013), and 6.42 ± 0.18 and 6.66 ± 0.18 mmol/L afterW320 and
C320, respectively (p ¼ 0.195). Serum glucose iAUC did neither
differ betweenW150 and C150 (p ¼ 0.152), nor betweenW320 and
C320 (p ¼ 0.577). Pooled analysis of the low-caloric vs. the high-
caloric products showed signiﬁcantly lower peak and iAUC serum
glucose concentration for the low-caloric vs the high-caloric
products (p < 0.001). There was no signiﬁcant interaction effect
between protein source and caloric density for the peak serum
glucose concentration (p ¼ 0.314), nor for serum glucose iAUC
(p ¼ 0.494).
Peak and iAUC serum insulin concentration did not differ be-
tweenW150 and C150 (p ¼ 0.915 for peak; p ¼ 0.782 for iAUC), nor
between W320 and C320 (p ¼ 0.989 for peak; p ¼ 0.261 for iAUC).
Pooled analysis of the low-caloric vs. the high-caloric products
showed a signiﬁcantly lower peak and iAUC serum insulin con-
centration for the low-caloric vs the high-caloric products
(p < 0.001). The interaction effect between protein source and
caloric density for peak serum insulin concentration (p ¼ 0.933), or
for serum insulin iAUC (p ¼ 0.335) was not signiﬁcant.
3.3. In vitro gastric coagulation
The leucine-enriched whey protein supplements did not yield
any measurable coagulates after gastric digestion, while casein
supplements did. Gastric digestion of C320 yielded a signiﬁcantly
higher total amount of coagulates than C150 (p ¼ 0.005). This was
due to a higher amount of coagulates of the middle diameter
fraction (D<1e2>) (p¼ 0.021), and a tendency for a higher amount of
coagulates of the smallest diameter fraction (D<0.25e1>) (p ¼ 0.051).
The largest diameter fraction, however, was not signiﬁcantly
different (p ¼ 0.691), (Fig. 4). The percentage of total coagulate
matter in D>2 was signiﬁcantly lower in C320 vs C150 (62.3 ± 9.0 vs
91.0 ± 1.4%, respectively; p¼ 0.035), while the percentage in D<1e2>
was signiﬁcantly higher (15.5 ± 3.6 vs 4.6 ± 0.8%, respectively;
p ¼ 0.043) and in D<0.25e1> tended to be higher (22.2 ± 6.4 vs
4.4 ± 0.6% respectively; p ¼ 0.051).
3.4. In vitro protein digestion rate
The vast majority of small peptides were released during the
intestinal phase of digestion for all supplements tested. The amount
of small peptides present early in the intestinal phase (t10min) was
signiﬁcantly higher in the casein supplements than the leucine-
enriched whey protein supplements of the same caloric density
(150 kcal: p ¼ 0.003 and 320 kcal p < 0.001). For the later samples
in the intestinal phase, these amounts were no longer signiﬁcantly
different (p > 0.0125). At t90, larger amounts of peptides tended to
be present in samples of low caloric supplements; W150 vs W320
(p ¼ 0.072) and C150 vs C320 (p ¼ 0.049) (Fig. 5A).
There were free AA present in the gastric phase of the leucine
enriched, whey protein supplements. These are most likely the free
branched chain amino acids (leucine, isoleucine, valine; all EAA)
that are present in the initial supplement. There was negligible
release of amino acids in the gastric phase.
In the early phase of intestinal digestion (t10 and t20), the total
amount of free AAwas signiﬁcantly higher for C320 than both C150
(p < 0.0125) and W320 (p < 0.0125). From t30 onwards, W150 was
signiﬁcantly higher than W320 (p < 0.0125) and from t60 onwards
also higher than C150 (p < 0.0125). At the end of the intestinal
phase (t90), both C150 and W320 were signiﬁcantly higher than
C320 (p < 0.001) (Fig. 5B).The amount of free EAA at t10 was
signiﬁcantly higher for C320 than for C150 and W320 (p < 0.001).
From t20 onwards, W150 was signiﬁcantly higher than C150
(p < 0.0125) and from t30 onwards also signiﬁcantly higher than
W320 (p < 0.0125). W320 was signiﬁcantly higher than C320 at t60
Fig. 2. Serum amino acids. Serum levels (EMM ± SE) of A) leucine, B) essentials amino
acids (EAA), and C) sum of amino acids (TAA) before and after ingestion (at T ¼ 0) of
Y.C. Luiking et al. / Clinical Nutrition 35 (2016) 48e58 53(p ¼ 0.0013) and t90 (p < 0.001) (Fig. 5C). After correction for the
initial difference in free EAA level between the leucine-enriched
whey protein supplements and casein supplement caloric equiva-
lents, the amount of free EAA forW150was still signiﬁcantly higher
than W320 from t30 onwards (p < 0.0125), and also higher than
C150 at t60 (p ¼ 0.006) and t90 (p < 0.001) (Fig. 5E).
The amount of free leucine was signiﬁcantly higher at all time
points for both leucine-enriched whey protein supplements than
for their casein supplement caloric equivalents (p < 0.0125). From
t30 onwards, W150 was also signiﬁcantly higher than W320
(p < 0.0125). For the casein supplements at t10, C320 was higher
than C150 (p ¼ 0.008), at t20 and t30 there was no signiﬁcant
difference (p ¼ 0.046 and p ¼ 0.865, respectively). At t60 and t90,
C150 was signiﬁcantly higher than C320 (p ¼ 0.008 and p < 0.001,
respectively) (Fig. 5D). After correction for the initial higher leucine
level, the amount of leucine in W150 was also signiﬁcantly higher
than W320 from t30 onwards (p < 0.0125), and also signiﬁcantly
higher than C150 at t90 (p < 0.001), but not at t60 (p ¼ 0.057)
(Fig. 5F).
SEC chromatograms of t90 samples indicate that peptides
smaller than 1kD constitute about 70% (68e72) of all soluble pro-
tein and peptides (data not shown). At that time point, there is on
average 4.5 g of free amino acids (Fig. 5B). Assuming all proteins
were dissolved at this point and free AA do indeed not contribute to
the signal, the estimated degree of digestion at t90 of the total 21 gr
of food protein and 1.3 gr of protein from digestive juices is 76%
(calculated as ((22.3e4.5)*0.7 þ 4.5)/22.3*100%), of which about
70% are peptides and 30% are amino acids.4. Discussion
In the current study, blood AA proﬁles after consumption of a
leucine-enriched whey protein nutritional supplement or an iso-
caloric and iso-nitrogenous casein protein supplement were
compared in healthy older men andwomen. In addition, the impact
of the caloric density of the products on the blood AA proﬁles was
analysed. Higher levels of TAA, EAA, and leucine were observed
after the leucine-enriched whey protein supplements compared to
the casein protein supplements. This effect was further augmented
by the low-caloric density of the formulation, both for the casein
and whey protein-containing supplements. As far as we are aware,
this is a novel observation as it resembles realistic protein amounts
in mixed meals. In accordance with in vivo data, gastric physico-
chemical behaviour in vitro was profoundly protein type depen-
dent; only the casein supplements clotted. The initial intestinal
protein digestion rate of casein supplements was higher than that
of whey protein supplements. The overall protein digestion rate
and cumulative release of AAs over 90-min, however, was higher
for whey supplements than their casein counterparts. In addition to
the protein type dependency, this was also caloric density depen-
dent, i.e. higher for 150 kcal than 320 kcal. These overall differences
in the in vitro data thus nicely ﬁt with the observed differences in
in vivo blood AA proﬁles. The results suggest that gastric coagula-
tion, likely impacting gastric emptying, and/or overall protein
digestion rate are determinants of amino acid proﬁles, while initial
enzymatic hydrolysis rate in the intestine is less important. The
observed differences in postprandial amino acid proﬁles in vivo,
therefore, appear to be at least partly mediated by the gastroin-
testinal behaviour of the products.the study products: leucine-enriched whey protein, 150 kcal (W150); casein protein,
150 kcal (C150); leucine-enriched whey protein, 320 kcal (W320); and casein protein,
320 kcal (C320), in healthy older subjects (n ¼ 12).
Fig. 3. Serum glucose and insulin. Serum levels (EMM ± SE) of A) glucose and B)
insulin before and after ingestion (at T ¼ 0) of the study products: leucine-enriched
whey protein, 150 kcal (W150); casein protein, 150 kcal (C150); leucine-enriched
whey protein, 320 kcal (W320); and casein protein, 320 kcal (C320), in healthy older
subjects (n ¼ 12).
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The leucine content in the leucine-enriched whey protein sup-
plements was 1.5-fold higher compared to the casein protein sup-
plements. This contributed to the difference in serum leucine
levels. However, despite the equal contents of EAA and TAA, these
proﬁles differed between the products and indicate the contribu-
tion of other aspects. Delayed gastric emptying of casein due to
gastric coagulation of the protein has been demonstrated [22], and
subsequent differences in intestinal behaviour between casein and
whey have been shown with intra-jejunal sampling [20,21,23] and
with the use of intrinsically labelled proteins [14]. It has been
demonstrated that the particle size has an impact on gastric
emptying. Solid matter needs to be broken down to <1e2 mm
particles prior to their stomach emptying [36]. Our in vitro data
conﬁrm gastric coagulation with casein speciﬁcally, but alsoindicate different digestion kinetics for whey and casein protein
supplements.
To our knowledge, the intestinal digestive properties of casein
and whey protein have not been extensively studied, especially in
mixed meals. We observed that the initial intestinal digestion rate
of casein-containing supplements was higher. This is in line with
other in vitro digestion studies, using human gastric and duodenal
aspirates. In these studies, caseins inmilk from several species were
digested very rapidly after being exposed to either human gastric or
duodenal juices, as compared to whey proteins [37,38].
Moreover, we observed in our study that the overall protein
digestion rate, as reﬂected by the cumulative levels of TAA, EAA and
leucine over the total 90-min intestinal digestion period, was
higher with the whey-containing supplements. Thus, digestive
properties of the whey and casein-containing supplements differ,
independent from metabolism and feedback mechanisms in the
body.
4.2. Effect of caloric density
Interestingly, a signiﬁcant interaction effect between protein
source and caloric density for the peak level of leucine and
(essential) amino acids was observed. This means that the effect of
calories is even more pronounced for the whey protein supplement
than for the casein protein supplement. Most previous studies
compared whey and casein products with no added calories from
fat and carbohydrates [14,17,18], and only one study used a mixed
meal [19]. So far, it has only been suggested that, by comparing
between studies, the difference in digestion rate for whey versus
casein in a mixed meal is less pronounced than when the proteins
are given without added calories [16,19]. In line with our observa-
tions, the co-ingestion of carbohydrates with casein protein low-
ered plasma AA levels in older adults [39], and also delayed
digestion and absorption kinetics using intrinsically labelled casein
[26]. Only one study in young adults showed lower peak plasma
levels of leucine, branched chain amino acids (BCAA) and EAAwhen
whey protein was co-ingested with carbohydrates [40]. Two
studies, in young adults with intrinsically labelled milk protein,
showed that the addition of carbohydrates and fat delays gastric
emptying of milk protein and slows the release of dietary nitrogen
to the periphery [27,41]. A larger caloric load is indeed known to
slow gastric emptying [24,25], but the impact on digestion and
absorption is less well known. In vitro, we observed that a higher
caloric density increased the amount of casein coagulates, and
especially the number of smaller sized particles. In addition to this
distinctive gastric behaviour, we observed that a higher caloric
density decreased the cumulative release of AA from the whey
protein supplements signiﬁcantly over the total 90-min intestinal
digestion period. It is possible that the smaller coagulates facilitated
the early phase of intestinal digestion with the high-caloric casein
product, as reﬂected in the initial higher level of small peptides and
amino acids. This effect was diminished later in the intestinal phase
when coagulates had disappeared. Thus, as well as potentially
having an effect on gastric emptying rate in vivo, caloric density
‘slows’ overall protein digestion rate in vitro.
4.3. Limitations and alternative explanations
While our data demonstrate that the observed differences in
serum amino acid proﬁles are mediated, at least in part, by the
gastrointestinal behaviour of the products, we cannot exclude other
metabolic effects that impact on serum amino acid levels. This is
relevant as the rate of dietary protein digestion and amino acid
absorption from the gut also modulate the postprandial metabolic
response [17,42]. This includes a larger inhibition of endogenous
Table 3
Serum amino acid concentrations at baseline and after intake of the study products in healthy older subjects (n ¼ 12).









Baseline (mmol/L) 109 ± 6.3 113 ± 6.5 110 ± 6.3 115 ± 5.7
Maximum (mmol/L)1 521 ± 15.1 260 ± 15.4 406 ± 14.5 228 ± 15.2 <0.001 <0.001 0.042 <0.001
iAUC (mmol/L*min)2 44,588 ± 1439 22,207 ± 1473 35,952 ± 1386 15,793 ± 1451 <0.001 <0.001 <0.001 <0.001
t1/2 (min)3 87 ± 5.4 119 ± 5.6 101 ± 5.2 118 ± 5.5 <0.001 0.015 0.867 0.003
EAA
Baseline (mmol/L) 859 ± 31.2 868 ± 35.0 887 ± 29.1 883 ± 30.6
Maximum (mmol/L) 2187 ± 57.0 1540 ± 57.5 1420 ± 56.8 1792 ± 55.0 <0.001 <0.001 0.023 <0.001
iAUC (mmol/L*min) 129,793 ± 5690 100,516 ± 5765 75,181 ± 5685 101,181 ± 5471 <0.001 <0.001 <0.001 <0.001
t1/2 (min) 83 ± 5.0 115 ± 5.1 117 ± 5.0 94 ± 4.8 <0.001 0.042 0.762 <0.001
TAA
Baseline (mmol/L) 2786 ± 46.5 2824 ± 37.3 2880 ± 55.1 2848 ± 60.1
Maximum (mmol/L) 4687 ± 111 3946 ± 111 4141 ± 108 3699 ± 110 <0.001 <0.001 0.003 <0.001
iAUC (mmol/L*min) 162,702 ± 12,979 143,018 ± 12,994 128,047 ± 12,684 105,525 ± 12,872 0.032 <0.001 <0.001 0.008
t1/2 (min) 78 ± 5.2 101 ± 5.3 87 ± 4.9 103 ± 5.1 <0.001 0.143 0.769 0.007
EAA, essential amino acids; AA, sum of amino acids.
Study products: leucine-enriched whey protein, 150 kcal (W150); casein protein, 150 kcal (C150); leucine-enriched whey protein, 320 kcal (W320); and casein protein,
320 kcal (C320).
1Maximum (or peak) level. 2Maximum minus baseline difference. 2Incremental area under the curve. 3Time to reach half the serum iAUC.
Statistical analysis was done by mixedmodel including serum albumin, serum CRP, and baseline serum outcome parameter concentration as covariates and subject as random
factor.
Baseline values were not different between the study products.
Y.C. Luiking et al. / Clinical Nutrition 35 (2016) 48e58 55protein breakdown [14,17], and greater splanchnic sequestration
[14,17] of casein compared with whey protein. Both may reduce the
systemic appearance of amino acids with casein. Similarly, the
addition of carbohydrates and fat lowers whole body protein
breakdown, which is even more pronounced in combination with
whey than with casein protein [17,19]. The observed higher insulin
levels after ingestion of the high caloric products could have
inhibited protein breakdown to a larger extent [43]. Moreover,
added carbohydrates have been shown to reduce protein oxidation
[27] and to increase splanchnic sequestration of dietary nitrogen
[41,44]. Thus, we cannot exclude that, besides and maybe partly
due to distinct gastrointestinal behaviour, inhibition of protein
breakdown and increased splanchnic sequestrationwith casein and
higher caloric content have also contributed to the lower serum
amino acid levels. Based on the amino levels only, we cannot
quantify how many amino acids came directly from the products
over time. Another limitation of the in vivo study could be that
results have been obtained in a healthy group of people that are 65
years and older. Given that the prevalence and incidence ofFig. 4. In vitro gastric coagulation. Coagulates formed during the gastric phase and
differentiated by their particles size (in mm). Means ± pooled standard error (n ¼ 3). *
signiﬁcantly different from C150 (Student's t-test; p < 0.05). N.D e not detected.gastrointestinal dysfunction, i.e. in the form of dysmotility, may
increase with age and in disease [45], it could be expected that the
differences would be augmented in a population that is not healthy.
In vitro models are an approximation of the dynamic situation
in vivo. When the conditions of gastric and intestinal phases of
in vitro digestion are ﬁxed, they make it possible to compare be-
tween products for gastric coagulation properties and hydrolysis
kinetics. Measurement of digestion and absorption in vivo is much
more invasive or requires the use of intrinsically labelled protein. In
our study, the pH was set to be equal for all products in the intes-
tinal phase. However, the 10 min of neutralization between the
gastric and intestinal phases were not sufﬁcient to bring the pH to
6.5; the casein products needed 20 min and the whey products
30 min to reach this value. This difference will likely have nega-
tively impacted the initial protein digestion kinetics, especially of
the whey products, since the pH was suboptimal for a longer
period. Moreover, it is known that the accumulation of products of
digestion in a closed system can limit enzymatic hydrolysis to
considerably less than 100%. At the end of the intestinal phase (t90),
we estimated that 76% was digested to end products, i.e. the
absorbable fraction of <1kD [33]. When comparing in vitro and
in vivo observations, the pattern of cumulative in vitro digestion of
free AA in our study resembled that of the in vivo serum AA proﬁle.
Besides the free AA, a large abundance of peptides in the absorbable
fraction will also and even faster appear as free AA in blood in vivo
[46] for which we cannot discriminate its origin. However, we did
not observe a difference in the cumulative peptide release in vitro
between the products in our study. A ﬁnal limitation of the study is
that we cannot discriminate between the effect of calories origi-
nating from carbohydrates or from fat.4.4. Relevance of the data
Postprandial blood levels of EAA and leucine are considered
relevant to stimulate muscle protein synthesis [13,14]. With
advancing age and disease, the threshold for anabolic stimuli to
increase muscle protein synthesis is likely to become higher [8,15].
The high postprandial levels of EAA and leucine that we observed
after ingestion of a leucine-enriched whey protein supplement in
healthy older subjects, therefore, seems preferable to provoke
Fig. 5. In vitro protein digestion. Accumulation of protein digestion products formed in the intestinal phase over time: A) peptides smaller than 1kD, B) total free AA, C) total free
EAA, D) free leucine, E) total free EAA corrected for the initial difference in free EAA in the supplements, and F) total leucine corrected for the initial difference in free leucine in the
supplements. Means ± pooled standard error.* signiﬁcantly different fromW150, y signiﬁcantly different from W320, z signiﬁcantly different from C150 (ANOVA univariate analysis
with LSD post hoc test and correction for multiple comparisons; p < 0.0125). The stomach phase is not shown, since negligible amounts of products were formed in this phase.
Y.C. Luiking et al. / Clinical Nutrition 35 (2016) 48e5856subsequent muscle protein synthesis also in older sarcopenic
adults. Moreover, a low caloric product favours higher postprandial
blood leucine and EAA levels and faster digestion. The impact of
energy density on serum amino acid proﬁles and gastrointestinal
digestion is likely relevant for muscle anabolism and subsequent
improvement of muscle mass, strength and function in older sar-
copenic adults, in order to counteract the negative impact on
quality of life, disability and hospitalization.
In conclusion, it was demonstrated in a healthy population of
people of 65 years and older, that consumption of a low caloric
leucine-enriched whey protein supplement provides a higher rise
in serum levels of TAA, EAA and leucine compared to casein or high
caloric products. These differences appear to bemediated at least inpart by the gastrointestinal behaviour of these nutritional compo-
sitions. This effect on postprandial amino acid proﬁles is promising
for stimulation of muscle protein synthesis in sarcopenic older
people with a low caloric leucine-enriched whey protein supple-
ment and for potential long-term effects on muscle mass, strength
and function. This requires further study.Statement of authorship
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